

Tanderil.

Contributors

Geigy Pharmaceuticals

Publication/Creation

[approximately 1961]

Persistent URL

<https://wellcomecollection.org/works/cjd74ufv>


License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome
collection**

Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL
TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL
TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL
TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL
TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL
TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL TANDERIL



Tanderil®

Major non-hormonal anti-inflammatory agent

Inflammation, the host's reaction to tissue injury, has been the subject of intensive research during the last decade and it has been shown that in certain conditions a controlled modification of the inflammatory process may be advantageous in speeding recovery. Thus an agent which significantly reduces the classic signs of swelling, pain, redness, and local pyrexia would also induce an early return to normal function in the injured area and shorten the patient's period of convalescence (1).

Tanderil® (Oxyphenbutazone) a potent non-steroid anti-inflammatory agent provides a rational means of modifying both the acute and chronic inflammatory reaction. Being non-hormonal, Tanderil does not have the disadvantages inherent in systemic corticosteroid therapy where increased steroid dosage needs, together with the 'steroid withdrawal syndrome' are marked therapeutic hazards.

The therapeutic effectiveness of Tanderil has been established in the following wide range of inflammatory disorders:—

- Bursitis, tenosynovitis 'fibrositis' (2)
- Sprains and strains, fractures, contusions, dislocations (3)
- Prolapsed internal haemorrhoids (4)
- Superficial thrombophlebitis (5)
- Uveitis, scleritis, keratitis (6)
- Post-operative inflammation and pain (7)

References

1. Connell, J. F., Rousselot, L. M., *Amer. J. Surg.*, **98**, 31 (1959).
2. Robichaux, E. B., *Gen. Pract.*, **24**, 14 (1961).
3. Connell, J. F., et al., *Amer. J. Surg.*, **101**, 435 (1961).
4. Todd, I. P., *Current Medicine and Drugs*, **2**, 1 (1961).
5. Pent, D., Rojas, J., *Obstet. Gynec.*, **16**, 206 (1960).
6. Werner, L. E. J., *Brit. J. Ophth.*, **44**, 755 (1960).
7. Miller, J. M., Ginsberg, M., et al, *Antibiotic Med.*, **7**, 109 (1960).
8. Hart, Dudley, F., Burley, D., *B. M. J.*, **1**, 1087 (1959).

Geigy

Tanderil®

Non-hormonal resolution of inflammation

The value of Tanderil therapy lies in its ability to bring about a prompt resolution of the acute and chronic inflammatory process associated with traumatic and non-traumatic inflammatory conditions, without incurring the therapeutic hazards inherent in steroid therapy.

In many acute inflammatory conditions a short course of Tanderil therapy:—

Rapidly controls the inflammatory process

Relieves associated pain by reducing tissue oedema

Hastens the return of normal function to the injured tissues

Shortens the patient's period of convalescence.

Dosage 100 mg tablets

In acute conditions

An initial dosage of 2 tablets two or three times daily (400-600 mg) for two or three days, followed by 1 tablet three or four times daily (300-400 mg) until the condition is resolved.

Tanderil should be taken in divided doses with food.

In chronic conditions

In the long-term treatment of chronic inflammatory conditions, maintenance doses of Tanderil remain consistently effective without the need to increase dosage. Hart and Burley(8) using Tanderil for periods of 3 to 12 months reported no evidence of intolerance in 14 patients using a daily dose of 300-400 mg Tanderil.

Being non-corticosteroid, Tanderil does not give rise to the clinical and therapeutic management problems frequently associated with systemic steroid therapy, such as hormonal imbalance and the 'steroid withdrawal syndrome'.

Geigy

Tanderil®

Major non-hormonal anti-inflammatory agent

Geigy

Indications

Tanderil® is indicated in the treatment of local inflammation of the soft tissues and musculo-skeletal system, and where there is an excessive inflammatory response in traumatic and non-traumatic inflammatory conditions.

'Fibrositis', synovitis, tenosynovitis, myositis, bursitis, sprains, strains, contusions, dislocations and fractures.

Contraindications

Tanderil is contraindicated in the presence of cardiac, renal or hepatic damage; history of peptic ulceration, drug allergy and blood dyscrasias.

Side-effects

Although seldom sufficiently serious to warrant discontinuing therapy, gastric irritation, and oedema due to sodium retention are the side-effects most frequently encountered.

Drug rash has also been reported.

Blood dyscrasias are rare complications and are usually reversible. Careful clinical supervision and routine blood counts during the initial weeks of therapy may be valuable in their early detection.

Dosage 100 mg tablets

2 tablets two or three times daily, (400-600 mg) with meals for two or three days, followed by 1 tablet three or four times daily (300-400 mg) with meals until remission of swelling and inflammation is achieved.

Patients with an active or suspected bacterial focus associated with the inflammatory reaction should receive concurrent antibiotic and/or surgical treatment.

Availability

Tanderil is available as coffee-coloured, sugar-coated tablets each containing 100 mg of 1-Phenyl-2-p-hydroxyphenyl-3,5-dioxo-4-n-butylpyrazolidine monohydrate.

Containers of	Basic N.H.S. Prices
50 tablets	14s. 0d.
250 tablets	65s. 8d.

Detailed literature describing any Geigy product will be supplied on request.

Geigy Pharmaceutical Company Ltd
Manchester 23